Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development

详细信息    查看全文

• 作者：Juan Wang ; Guixiang Tai
• 刊名：Targeted Oncology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：11
• 期：6
• 页码：723-738
• 全文大小：
• 刊物主题：Oncology; Biomedicine, general;
• 出版者：Springer International Publishing
• ISSN：1776-260X
• 卷排序：11

文摘

Hepatocellular carcinoma (HCC) is among the most frequently occurring cancers and the leading causes of cancer mortality worldwide. Identification of the signaling pathways regulating liver carcinogenesis is critical for developing novel chemoprevention and targeted therapies. C-Jun N-terminal kinase (JNK) is a member of a larger group of serine/threonine (Ser/Thr) protein kinases known as the mitogen-activated protein kinase (MAPK) family. JNK is an important signaling component that converts external stimuli into a wide range of cellular responses, including cell proliferation, differentiation, survival, migration, invasion, and apoptosis, as well as the development of inflammation, fibrosis, cancer growth, and metabolic diseases. Because of the essential roles of JNK in these cellular functions, deregulated JNK is often found to contribute to the development of HCC. Recently, the functions and molecular mechanisms of JNK in HCC development have been addressed using mouse models and human HCC cell lines. Furthermore, recent studies demonstrate that the activation of JNK by oncogenes can promote the development of cancers by regulating the transforming growth factor (TGF)-β/Smad pathway, which makes the oncogenes/JNK/Smad signaling pathway an attractive target for cancer therapy. Additionally, JNK-targeted therapy has a broad potential for clinical applications. In summary, we are convinced that promising new avenues for the treatment of HCC by targeting JNK are on the horizon, which will undoubtedly lead to better, more effective, and faster therapies in the years to come.References1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.PubMedCrossRefGoogle Scholar2.Farazi PA, Depinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.PubMedCrossRefGoogle Scholar3.Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84–101.PubMedCrossRefGoogle Scholar4.de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.PubMedCrossRefGoogle Scholar5.El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.PubMedCrossRefGoogle Scholar6.Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47:S2–6.PubMedPubMedCentralCrossRefGoogle Scholar7.Li QS, Liu GM, Shao D, Wang J, Yuan HY, Chen TX, et al. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells. Int J Biochem Cell Biol. 2015;59:116–25.PubMedCrossRefGoogle Scholar8.Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev. 2002;12:14–21.PubMedCrossRefGoogle Scholar9.Ekihiro S, Brenner DA, Michael K. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012;143:307–20.CrossRefGoogle Scholar10.Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239–52.PubMedCrossRefGoogle Scholar11.Whitmarsh AJ, Kuan CY, Kennedy NJ, Kelkar N, Haydar TF, Mordes JP, et al. Requirement of the JIP1 scaffold protein forstress-induced JNK activation. Genes Dev. 2001;15:2421–32.PubMedPubMedCentralCrossRefGoogle Scholar12.Owens DM, Keyse SM. Differential regulation of MAP kinasesignalling by dual-specificity protein phosphatases. Oncogene. 2007;26:3203–13.PubMedCrossRefGoogle Scholar13.Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR, et al. The NF-kappaB-mediated control of the JNK cascade in theantagonism of programmed cell death in health and disease. Cell Death Differ. 2006;13:712–29.PubMedCrossRefGoogle Scholar14.Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Dérijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996;15:2760–70.PubMedPubMedCentralGoogle Scholar15.Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev. 2006;70:1061–95.PubMedPubMedCentralCrossRefGoogle Scholar16.Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–49.PubMedCrossRefGoogle Scholar17.Matsuzaki K. Smad phospho-isoforms direct context-dependent TGF-β signaling. Cytokine Growth Factor Rev. 2013;24:385–99.PubMedCrossRefGoogle Scholar18.Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature. 1991;354:494–6.PubMedCrossRefGoogle Scholar19.Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 1995;92:11746–50.PubMedPubMedCentralCrossRefGoogle Scholar20.Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J. 1997;16:2634–45.PubMedPubMedCentralCrossRefGoogle Scholar21.Behrens A, Jochum W, Sibilia M, Wagner EF. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene. 2000;19:2657–63.PubMedCrossRefGoogle Scholar22.Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov. 2003;2:554–65.PubMedCrossRefGoogle Scholar23.Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93:1062–74.PubMedCrossRefGoogle Scholar24.Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76:1025–37.PubMedCrossRefGoogle Scholar25.Schutte J, Minna JD, Birrer MJ. Deregulated expression of human c-Jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A. 1989;86:2257–61.PubMedPubMedCentralCrossRefGoogle Scholar26.Wang SE, Yu Y, Criswell TL, Debusk LM, Lin PC, Zent R, et al. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene. 2010;29:3335–48.PubMedPubMedCentralCrossRefGoogle Scholar27.Sekimoto G, Matsuzaki K, Yoshida K, Mori S, Murata M, Seki T, et al. Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res. 2007;67:5090–6.PubMedCrossRefGoogle Scholar28.Yamagata H, Matsuzaki K, Mori S, Yoshida K, Tahashi Y, Furukawa F, et al. Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res. 2005;65:157–65.PubMedGoogle Scholar29.Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46:48–57.PubMedCrossRefGoogle Scholar30.Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Tahashi Y, Mori S, et al. Hepatitis Bvirus X protein shifts human hepatic TGF-beta signaling from tumor-suppression to oncogenesis in early chronichepatitis B. Hepatology. 2009;49:1203–17.PubMedCrossRefGoogle Scholar31.Tsutsumi T, Suzuki T, Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology. 2002;304:415–24.PubMedCrossRefGoogle Scholar32.Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A. 2006;103:10544–51.PubMedPubMedCentralCrossRefGoogle Scholar33.Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest. 2008;118:3943–53.PubMedPubMedCentralCrossRefGoogle Scholar34.Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol. 2009;50:323–33.PubMedCrossRefGoogle Scholar35.Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 2011;25:634–45.PubMedPubMedCentralCrossRefGoogle Scholar36.Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene. 2007;26:3172–84.PubMedCrossRefGoogle Scholar37.Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153–8.PubMedPubMedCentralCrossRefGoogle Scholar38.Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869–73.PubMedCrossRefGoogle Scholar39.Guo L, Guo Y, Xiao S, Shi X. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci. 2005;77:1869–78.PubMedCrossRefGoogle Scholar40.Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 2007;67:3601–8.PubMedCrossRefGoogle Scholar41.Hsiang CY, Wu SL, Chen JC, Lo HY, Li CC, Chiang SY, et al. Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-kappaB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: association with the invasive potential. Toxicol Lett. 2007;171:78–86.PubMedCrossRefGoogle Scholar42.Qian AR, Zhang W, Cao JP, Yang PF, Gao X, Wang Z, et al. Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2008;27:50.PubMedPubMedCentralCrossRefGoogle Scholar43.Cho SB, Park YL, Park SJ, Park SY, Lee WS, Park CH, et al. KITENIN is associated with activation of AP-1 target genes via MAPK cascades signaling in human hepatocellular carcinoma progression. Oncol Res. 2011;19:115–23.PubMedCrossRefGoogle Scholar44.Park YH, Shin HJ, Kim SU, Kim JM, Kim JH, Bang DH, et al. iNOS promotes HBx-induced hepatocellular carcinoma via upregulation of JNK activation. Biochem Biophys Res Commun. 2013;435:244–9.PubMedCrossRefGoogle Scholar45.Wang L, Zhu R, Huang Z, Li H, Zhu H. Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci. 2013;58:2223–6.PubMedCrossRefGoogle Scholar46.Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, Massoumi R. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis. 2014;35:461–8.PubMedCrossRefGoogle Scholar47.Carr BI, Cavallini A, D’Alessandro R, Refolo MG, Lippolis C, Mazzocca A, et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer. 2014;14:43.PubMedPubMedCentralCrossRefGoogle Scholar48.Yang XH, Zheng X, Cao JG, Xiang HL, Liu F, Lv Y. 8-Bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK. World J Gastroenterol. 2010;16:3385–93.PubMedPubMedCentralCrossRefGoogle Scholar49.Choedon T, Shukla SK, Kumar V. Chemopreventive and anti-cancer properties of the aqueous extract of flowers of Butea monosperma. J Ethnopharmacol. 2010;129:208–13.PubMedCrossRefGoogle Scholar50.Lee EK, Kim HJ, Lee KJ, Lee HJ, Lee JS, Kim DG, et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol. 2011;38:325–33.PubMedGoogle Scholar51.Xiao CL, Tao ZH, Guo L, Li WW, Wan JL, Sun HC, et al. Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice. BMC Cancer. 2011;11:150.PubMedPubMedCentralCrossRefGoogle Scholar52.Matsushima-Nishiwaki R, Adachi S, Yoshioka T, Yasuda E, Yamagishi Y, Matsuura J, et al. Suppression by heat shock protein 20 of hepatocellular carcinoma cell proliferation via inhibition of the mitogen-activated protein kinases and AKT pathways. J Cell Biochem. 2011;112:3430–9.PubMedCrossRefGoogle Scholar53.Honma Y, Shimizu S, Takehara T, Harada M. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. J Gastroenterol. 2014;49:517–26.PubMedCrossRefGoogle Scholar54.Xu L, Wang T, Meng WY, Wei J, Ma JL, Shi M, et al. Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression. Oncol Rep. 2015;33:1057–63.PubMedGoogle Scholar55.Li H, Li Y, Liu D, Liu J. LPS promotes epithelial-mesenchymal transition and activation of TLR4/JNK signaling. Tumour Biol. 2014;35:10429–35.PubMedCrossRefGoogle Scholar56.Dong YQ, Lu CW, Zhang L, Yang J, Hameed W, Chen W. Toll-like receptor 4 signaling promotes invasion of hepatocellular carcinoma cells through MKK4/JNK pathway. Mol Immunol. 2015;68:671–83.PubMedCrossRefGoogle Scholar57.Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874–85.PubMedPubMedCentralCrossRefGoogle Scholar58.Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20:332–42.PubMedCrossRefGoogle Scholar59.Chou CH, Huang MJ, Chen CH, Shyu MK, Huang J, Hung JS, et al. Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway. Oncotarget. 2015;6:6123–35.PubMedPubMedCentralCrossRefGoogle Scholar60.Joshi S, Kumar S, Choudhury A, Ponnusamy MP, Batra SK. Altered Mucins (MUC) trafficking in benign and malignant conditions. Oncotarget. 2014;5:7272–84.PubMedPubMedCentralCrossRefGoogle Scholar61.Alam M, Rajabi H, Ahmad R, Jin C, Kufe D. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget. 2014;5:2622–34.PubMedPubMedCentralCrossRefGoogle Scholar62.Horm TM, Schroeder JA. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adhes Migr. 2013;7:187–98.CrossRefGoogle Scholar63.Li QS, Wang FL, Liu GM, Yuan HY, Chen TX, Wang J, et al. Impact of Mucin1 knockdown on the phenotypic characteristics of the human hepatocellular carcinoma cell line SMMC-7721. Oncol Rep. 2014;31:2811–9.PubMedGoogle Scholar64.Chen Q, Li D, Ren J, Li C, Xiao ZX. MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress. Biochem Biophys Res Commun. 2013;440:179–83.PubMedCrossRefGoogle Scholar65.Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe DW. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005;65:10413–22.PubMedCrossRefGoogle Scholar66.Li YQ, Kuwahara H, Ren J, Wen GY, Kufe DW. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem. 2001;276:6061–4.PubMedCrossRefGoogle Scholar67.Pandey P, Kharbanda S, Kufe DW. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res. 1995;55:4000–3.PubMedGoogle Scholar68.Wei XL, Xu H, Kufe DW. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 2007;67:1853–8.PubMedCrossRefGoogle Scholar69.Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013;32:1073–81.PubMedCrossRefGoogle Scholar70.Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem. 2001;276:13057–64.PubMedCrossRefGoogle Scholar71.Merlin J, Stechly L, de Beaucé S, Monté D, Leteurtre E, van Seuningen I, et al. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene. 2011;30:2514–25.PubMedCrossRefGoogle Scholar72.Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S, et al. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signaling. Nat Cell Biol. 2007;9:1419–27.PubMedPubMedCentralCrossRefGoogle Scholar73.Nagata H, Hatano E, Tada M, Murata M, Kitamura K, Asechi H, et al. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology. 2009;49:1944–53.PubMedCrossRefGoogle Scholar74.Li QS, Liu GM, Yuan HY, Wang J, Guo YY, Chen TX, et al. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells. Oncotarget. 2015;6:4253–65.PubMedPubMedCentralCrossRefGoogle Scholar75.Wang J, Liu GM, Li QS, Wang F, Xie F, Zhai RP, et al. Mucin1 promotes the migration and invasion of hepatocellular carcinoma cells via JNK-mediated phosphorylation of Smad2 at the C-terminal and linker regions. Oncotarget. 2015;6:19264–78.PubMedPubMedCentralCrossRefGoogle Scholar76.Yamaguchi T, Matsuzaki K, Inokuchi R, Kawamura R, Yoshida K, Murata M, et al. Phosphorylated Smad2 and Smad3 signaling: shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. Hepatol Res. 2013;43:1327–42.PubMedCrossRefGoogle Scholar77.Deng YR, Yoshida K, Jin QL, Murata M, Yamaguchi T, Tsuneyama K, et al. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol. 2014;176:102–11.PubMedPubMedCentralCrossRefGoogle Scholar78.Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005;54:1024–33.PubMedPubMedCentralCrossRefGoogle Scholar79.Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol. 2009;15:513–20.PubMedPubMedCentralCrossRefGoogle Scholar80.Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007;27:155–62.PubMedCrossRefGoogle Scholar81.Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A. JNK activation is critical for Aplidin-induced apoptosis. Oncogene. 2004;23:4673–80.PubMedCrossRefGoogle Scholar82.Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3K/Akt signaling pathways. Apoptosis. 2011;16:1028–41.PubMedCrossRefGoogle Scholar83.Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem. 2006;281:12093–101.PubMedCrossRefGoogle Scholar84.Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem. 2006;281:21256–65.PubMedCrossRefGoogle Scholar85.Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene. 2008;27:6245–51.PubMedPubMedCentralCrossRefGoogle Scholar86.Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:360–9.PubMedPubMedCentralCrossRefGoogle Scholar87.Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007;56:1124–31.PubMedPubMedCentralCrossRefGoogle Scholar88.Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res. 2003;63:8323–9.PubMedGoogle Scholar89.Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, et al. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010;70:9309–18.PubMedCrossRefGoogle Scholar90.Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010;139:1762–73. 1773 e1–5.PubMedPubMedCentralCrossRefGoogle Scholar91.Liao YJ, Bai HY, Li ZH, Zou J, Chen JW, Zheng F, et al. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell Death Dis. 2014;5:e1137.PubMedPubMedCentralCrossRefGoogle Scholar92.Zhang Z, Miao L, Lv C, Sun H, Wei S, Wang B, et al. Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells. Cell Death Dis. 2013;4:e657.PubMedPubMedCentralCrossRefGoogle Scholar93.Wang C, Chen T, Zhang N, Yang M, Li B, Lü X, et al. Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB. J Biol Chem. 2009;284:3804–13.PubMedCrossRefGoogle Scholar94.Song IS, Jun SY, Na HJ, Kim HT, Jung SY, Ha GH, et al. Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis. Gastroenterology. 2012;143:1341–51.PubMedCrossRefGoogle Scholar95.Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987–1000.PubMedCrossRefGoogle Scholar96.Nehra V, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci. 2001;46:2347–52.PubMedCrossRefGoogle Scholar97.Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437–43.PubMedCrossRefGoogle Scholar98.Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NFkappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004;99:1708–17.PubMedCrossRefGoogle Scholar99.de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002;21:219–23.PubMedCrossRefGoogle Scholar100.Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab. 2006;291:E275–81.PubMedCrossRefGoogle Scholar101.Czaja MJ. Cell signaling in oxidative stress-induced liver injury. Semin Liver Dis. 2007;27:378–89.PubMedCrossRefGoogle Scholar102.Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333–6.PubMedCrossRefGoogle Scholar103.Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology. 2006;43:163–72.PubMedCrossRefGoogle Scholar104.Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology. 2009;49:87–96.PubMedPubMedCentralCrossRefGoogle Scholar105.Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134:568–76.PubMedCrossRefGoogle Scholar106.Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A. 2003;100:2432–7.PubMedPubMedCentralCrossRefGoogle Scholar107.Donovan N, Becker EB, Konishi Y, Bonni A. JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem. 2002;277:40944–9.PubMedCrossRefGoogle Scholar108.Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol. 1999;19:8469–78.PubMedPubMedCentralCrossRefGoogle Scholar109.Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem. 2009;284:26591–602.PubMedPubMedCentralCrossRefGoogle Scholar110.Pagliassotti MJ, Wei Y, Wang D. Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity. Endocrinology. 2007;148:3338–45.PubMedCrossRefGoogle Scholar111.Mucha SR, Rizzani A, Gerbes AL, Camaj P, Thasler WE, Bruns CJ, et al. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. Gut. 2009;58:688–98.PubMedCrossRefGoogle Scholar112.Aderca I, Moser CD, Veerasamy M, Bani-Hani AH, Bonilla-Guerrero R, Ahmed K, et al. The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol. 2008;49:373–83.PubMedPubMedCentralCrossRefGoogle Scholar113.Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001;108:73–81.PubMedPubMedCentralCrossRefGoogle Scholar114.Eynott PR, Xu L, Bennett BL, Noble A, Leung SY, Nath P, et al. Effect of an inhibitor of Jun N-terminal protein kinase, SP600125, in single allergen challenge in sensitized rats. Immunology. 2004;112:446–53.PubMedPubMedCentralCrossRefGoogle Scholar115.Miyamoto-Yamasaki Y, Yamasaki M, Tachibana H, Yamada K. Induction of endoreduplication by a JNK inhibitor SP600125 in human lung carcinoma A 549 cells. Cell Biol Int. 2007;31:1501–6.PubMedCrossRefGoogle Scholar116.Kim JA, Lee J, Margolis RL, Fotedar R. SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene. 2010;29:1702–16.PubMedPubMedCentralCrossRefGoogle Scholar117.Jemaà M, Vitale I, Kepp O, Berardinelli F, Galluzzi L, Senovilla L, et al. Selective killing of p53-deficient cancer cells by SP600125. EMBO Mol Med. 2012;4:500–14.PubMedPubMedCentralCrossRefGoogle Scholar118.Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene. 2004;23:596–604.PubMedCrossRefGoogle Scholar119.Kuntzen C, Sonuc N, De Toni EN, Opelz C, Mucha SR, Gerbes AL, et al. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res. 2005;65:6780–8.PubMedCrossRefGoogle Scholar120.Lu YY, Chen TS, Wang XP, Qu JL, Chen M. The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells. FEBS Lett. 2010;584:4019–26.PubMedCrossRefGoogle Scholar121.Kim JH, Chae M, Choi AR, Sik Kim H, Yoon S. SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. Eur J Pharmacol. 2014;723:141–7.PubMedCrossRefGoogle Scholar122.Zhang C, Zhang J, Li X, Sun N, Yu R, Zhao B, et al. Huaier aqueous extract induces hepatocellular carcinoma cells arrest in S phase via JNK signaling pathway. Evid Based Complement Alternat Med. 2015;2015:171356.PubMedPubMedCentralGoogle Scholar123.Wu JR, Hu CT, You RI, Pan SM, Cheng CC, Lee MC, et al. Hydrogen peroxide inducible clone-5 mediates reactive oxygen species signaling for hepatocellular carcinoma progression. Oncotarget. 2015;6:32526–44.PubMedPubMedCentralGoogle Scholar124.Kim MO, Lee HS, Chin YW, Moon DO, Ahn JS. Gartanin induces autophagy through JNK activation which extenuates caspase-dependent apoptosis. Oncol Rep. 2015;34:139–46.PubMedGoogle Scholar125.Uehara T, Xi Peng X, Bennett B, Satoh Y, Friedman G, Currin R, et al. c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation. 2004;78:324–32.PubMedCrossRefGoogle Scholar126.Vasilevskaya IA, Selvakumaran M, Hierro LC, Goldstein SR, Winkler JD, O’Dwyer PJ. Inhibition of jnk sensitizes hypoxic colon cancer cells to dna-damaging agents. Clin Cancer Res. 2015;21:4143–52.PubMedPubMedCentralCrossRefGoogle Scholar127. www.Clinicaltrials.gov; Trial Identifier NCT00126893.128.Plantevin Krenitsky V, Nadolny L, Delgado M, Ayala L, Clareen SS, Hilgraf R, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett. 2012;22:1433–8.PubMedCrossRefGoogle Scholar129.Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis. 2012;71:737–45.PubMedCrossRefGoogle Scholar130. www.Clinicaltrials.gov. Trial Identifier NCT01466725 and NCT01203943.131.Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland JP, Vitte PA. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl)ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminalprotein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther. 2004;310:25–32.PubMedCrossRefGoogle Scholar132.Ferrandi C, Ballerio R, Gaillard P, Giachetti C, Carboni S, Vitte PA, et al. Inhibition of c-Jun N-terminal kinase decreasescardiomyocyte apoptosis and infarct size after myocardial ischemiaand reperfusion in anaesthetized rats. Br J Pharmacol. 2004;142:953–60.PubMedPubMedCentralCrossRefGoogle Scholar133.Cerbone A, Toaldo C, Pizzimenti S, Pettazzoni P, Dianzani C, Minelli R, et al. AS601245, an anti-inflammatory JNK inhibitor, and clofibrate have a synergistic effect in inducing cell responses and in affecting the gene expression profile in CaCo-2 colon cancer cells. PPAR Res. 2012;2012:203–10.CrossRefGoogle Scholar134.Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012;19:140–54.PubMedPubMedCentralCrossRefGoogle Scholar135.Beydoun T, Deloche C, Perino J, Kirwan BA, Combette JM, Behar-Cohen F. Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study. J Ocul Pharmacol Ther. 2015;31:93–9.PubMedCrossRefGoogle Scholar136. www.clinicaltrials.gov. Trial Identifier NCT02508337 and NCT02235272.137.Suckfuell M, Lisowska G, Domka W, Kabacinska A, Morawski K, Bodlaj R, et al. Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study. Otol Neurotol. 2014;35(8):1317–26.PubMedCrossRefGoogle Scholar138. www.clinicaltrials.gov. Trial Identifier NCT00802425 and NCT02561091.139.El Zaoui I, Touchard E, Berdugo M, Abadie C, Kowalczuk L, Deloche C, et al. Subconjunctival injection of XG-102, a c-Jun N-terminal kinase inhibitor peptide, in the treatment of endotoxin-induced uveitis in rats. J Ocul Pharmacol Ther. 2015;31:17–24.PubMedCrossRefGoogle Scholar140.Touchard E, Omri S, Naud MC, Berdugo M, Deloche C, Abadie C, et al. A peptide inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2010;51:4683–93.PubMedCrossRefGoogle Scholar141.Sclip A, Tozzi A, Abaza A, Cardinetti D, Colombo I, Calabresi P, et al. c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death Dis. 2014;5:e1019.PubMedPubMedCentralCrossRefGoogle Scholar142.Ploia C, Antoniou X, Sclip A, Grande V, Cardinetti D, Colombo A, et al. JNK plays a key role in tau hyperphosphorylation in Alzheimer’s disease models. J Alzheimers Dis. 2011;26:315–29.PubMedGoogle Scholar143.Kersting S, Behrendt V, Kersting J, Reinecke K, Hilgert C, Stricker I, et al. The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium. J Inflamm Res. 2013;6:71–81.PubMedPubMedCentralCrossRefGoogle Scholar144.Reinecke K, Eminel S, Dierck F, Roessner W, Kersting S, Chromik AM, et al. The JNK inhibitor XG-102 protects against TNBS-induced colitis. PLoS One. 2012;7:e30985.PubMedPubMedCentralCrossRefGoogle Scholar145.Eshraghi AA, Gupta C, Van De Water TR, Bohorquez JE, Garnham C, Bas E, et al. Molecular mechanisms involved in cochlear implantation trauma and the protection of hearing and auditory sensory cells by inhibition of c-Jun-N-terminal kinase signaling. Laryngoscope. 2013;123 Suppl 1:S1–14.PubMedCrossRefGoogle Scholar146.Repici M, Chen X, Morel MP, Doulazmi M, Sclip A, Cannaya V, et al. Specific inhibition of the JNK pathway promotes locomotor recovery and neuroprotection after mouse spinal cord injury. Neurobiol Dis. 2012;46:710–21.PubMedCrossRefGoogle Scholar147.Guma M, Ronacher LM, Firestein GS, Karin M, Corr M. JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis Rheum. 2011;63:1603–12.PubMedPubMedCentralCrossRefGoogle Scholar148.Michel-Monigadon D, Bonny C, Hirt L. c-Jun N-terminal kinase pathway inhibition in intracerebral hemorrhage. Cerebrovasc Dis. 2010;29:564–70.PubMedCrossRefGoogle Scholar149.Liu JR, Zhao Y, Patzer A, Staak N, Boehm R, Deuschl G, et al. The c-Jun N-terminal kinase (JNK) inhibitor XG-102 enhances the neuroprotection of hyperbaric oxygen after cerebral ischaemia in adult rats. Neuropathol Appl Neurobiol. 2010;36:211–24.PubMedCrossRefGoogle Scholar150.Omotehara Y, Hakuba N, Hato N, Okada M, Gyo K. Protection against ischemic cochlear damage by intratympanic administration of AM-111. Otol Neurotol. 2011;32:1422–7.PubMedCrossRefGoogle Scholar151.Nijboer CH, Bonestroo HJ, Zijlstra J, Kavelaars A, Heijnen CJ. Mitochondrial JNK phosphorylation as a novel therapeutic target to inhibit neuroinflammation and apoptosis after neonatal ischemic brain damage. Neurobiol Dis. 2013;54:432–44.PubMedCrossRefGoogle Scholar152.Grindal TC, Sampson EM, Antonelli PJ. AM-111 prevents hearing loss from semicircular canal injury in otitis media. Laryngoscope. 2010;120(1):178–82.PubMedGoogle Scholar153.Gao YJ, Cheng JK, Zeng Q, Xu ZZ, Decosterd I, Xu X, et al. Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. Exp Neurol. 2009;219:146–55.PubMedPubMedCentralCrossRefGoogle Scholar154.Strittmatter F, Walther S, Gratzke C, Göttinger J, Beckmann C, Roosen A, et al. Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3. Br J Pharmacol. 2012;166:1926–35.PubMedPubMedCentralCrossRefGoogle Scholar155.Posthumadeboer J, van Egmond PW, Helder MN, de Menezes RX, Cleton-Jansen AM, Beliën JA, et al. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget. 2012;3:1169–81.PubMedCrossRefGoogle Scholar156.Stebbins JL, De SK, Machleidt T, Becattini B, Vazquez J, Kuntzen C, et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A. 2008;105:16809–13.PubMedPubMedCentralCrossRefGoogle Scholar157.Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001;98:13681–6.PubMedPubMedCentralCrossRefGoogle Scholar158.Koch P, Gehringer M, Laufer SA. Inhibitors of c-Jun N-terminal kinases: an update. J Med Chem. 2015;58:72–95.PubMedCrossRefGoogle Scholar159.Fabian MA, Biggs 3rd WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23:329–69.PubMedCrossRefGoogle Scholar160.Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK, et al. JNK mediates hepatic ischemia reperfusion injury. J Hepatol. 2005;42:850–9.PubMedCrossRefGoogle Scholar161.Li Q, Song XM, Ji YY, Jiang H, Xu LG. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem Biophys Res Commun. 2013;440:701–6.PubMedCrossRefGoogle Scholar162.Wiegler K, Bonny C, Coquoz D, Hirt L. The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator. Cerebrovasc Dis. 2008;26:360–6.PubMedCrossRefGoogle Scholar163.Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, et al. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci. 2006;26:3551–60.PubMedCrossRefGoogle Scholar164.Davoli E, Sclip A, Cecchi M, Cimini S, Carrà A, Salmona M, et al. Determination of tissue levels of a neuroprotectant drug: the cell permeable JNK inhibitor peptide. J Pharmacol Toxicol Methods. 2014;70:55–61.PubMedCrossRefGoogle Scholar165.Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta. 2010;1804:463–75.PubMedCrossRefGoogle Scholar166.Barr RK, Boehm I, Attwood PV, Watt PM, Bogoyevitch MA. The criticalfeatures and the mechanism of inhibition of a kinase interaction motif-basedpeptide inhibitor of JNK. J Biol Chem. 2004;279:36327–38.PubMedCrossRefGoogle ScholarCopyright information© Springer International Publishing Switzerland 2016Authors and AffiliationsJuan Wang1Guixiang Tai1Email author1.Department of Immunology, College of Basic Medical SciencesJilin UniversityChangchunChina About this article CrossMark Publisher Name Springer International Publishing Print ISSN 1776-2596 Online ISSN 1776-260X About this journal Reprints and Permissions Co-published with